Literature DB >> 32551948

Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis.

Chuan-Chin Huang1,2, Mercedes C Becerra2, Roger Calderon3, Carmen Contreras3, Jerome Galea4, Louis Grandjean5,6,7, Leonid Lecca3, Rosa Yataco3, Zibiao Zhang1,2, Megan Murray1,2.   

Abstract

Rationale: The World Health Organization recommends the use of isoniazid (INH) alone or in combination with rifapentine to treat latent tuberculosis infections. The recent rise of drug-resistant tuberculosis has complicated the choice of treatment regimen for latent tuberculosis infection.
Objectives: To evaluate the effects of INH preventive therapy on the contacts of patients with multidrug-resistant tuberculosis.
Methods: In a prospective cohort study conducted between September 2009 and August 2012, we identified 4,500 index patients with tuberculosis and 14,044 tuberculosis-exposed household contacts who we followed for 1 year for the occurrence of incident tuberculosis disease. Although Peruvian national guidelines specify that INH preventive therapy should be provided to contacts aged 19 years old or younger, only half this group received INH preventive therapy.Measurements and Main
Results: Among 4,216 contacts under 19 years of age, 2,106 contacts (50%) initiated INH preventive therapy at enrollment. The protective effect of INH was more extreme in contacts exposed to drug-sensitive tuberculosis (adjusted hazard ratio, 0.30; 95% confidence interval, 0.18-0.48) and to multidrug-resistant tuberculosis (adjusted hazard ratio, 0.19; 95% confidence interval, 0.05-0.66) compared with those exposed to mono-INH-resistant tuberculosis (adjusted hazard ratio, 0.80; 95% confidence interval, 0.23-2.80). In the second independent study, tuberculosis occurred in none of the 76 household contacts who received INH preventive therapy compared with 3% (8 of 273) of those who did not.Conclusions: Household contacts who received INH preventive therapy had a lower incidence of tuberculosis disease even when they had been exposed to an index patient with multidrug-resistant tuberculosis. INH may have a role in the management of latent multidrug-resistant tuberculosis infection.

Entities:  

Keywords:  INH; INH preventive therapy; multidrug-resistant tuberculosis; tuberculosis

Mesh:

Substances:

Year:  2020        PMID: 32551948      PMCID: PMC7560814          DOI: 10.1164/rccm.201908-1576OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  26 in total

1.  Proportional hazards models with frailties and random effects.

Authors:  John O'Quigley; Janez Stare
Journal:  Stat Med       Date:  2002-11-15       Impact factor: 2.373

Review 2.  Control of iron metabolism in Mycobacterium tuberculosis.

Authors:  G Marcela Rodriguez
Journal:  Trends Microbiol       Date:  2006-06-06       Impact factor: 17.079

3.  Isoniazid induces a monocytic-like phenotype in HL-60 cells.

Authors:  Dinesh Babu; Saifur R Khan; Nutan Srivastava; Lindsey Yeon Kyoung Suh; Andrew G Morgan; Naif Aljuhani; Richard P Fahlman; Arno G Siraki
Journal:  Arch Biochem Biophys       Date:  2019-01-22       Impact factor: 4.013

4.  Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection.

Authors:  Alimuddin Zumla; Rifat Atun; Markus Maeurer; Peter Mwaba; Zhenkun Ma; Justin O'Grady; Matthew Bates; Keertan Dheda; Michael Hoelscher; John Grange
Journal:  Trop Med Int Health       Date:  2011-01       Impact factor: 2.622

Review 5.  Preventive therapy for latent tuberculosis infection-the promise and the challenges.

Authors:  G J Fox; C C Dobler; B J Marais; J T Denholm
Journal:  Int J Infect Dis       Date:  2016-11-18       Impact factor: 3.623

Review 6.  Iron, mycobacteria and tuberculosis.

Authors:  Colin Ratledge
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

Review 7.  Isoniazid: an update on the multiple mechanisms for a singular action.

Authors:  V Bernardes-Génisson; C Deraeve; A Chollet; J Bernadou; G Pratviel
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

8.  Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.

Authors: 
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

9.  Mycobacterial p(1)-type ATPases mediate resistance to zinc poisoning in human macrophages.

Authors:  Hélène Botella; Pascale Peyron; Florence Levillain; Renaud Poincloux; Yannick Poquet; Irène Brandli; Chuan Wang; Ludovic Tailleux; Sylvain Tilleul; Guillaume M Charrière; Simon J Waddell; Maria Foti; Geanncarlo Lugo-Villarino; Qian Gao; Isabelle Maridonneau-Parini; Philip D Butcher; Paola Ricciardi Castagnoli; Brigitte Gicquel; Chantal de Chastellier; Olivier Neyrolles
Journal:  Cell Host Microbe       Date:  2011-09-15       Impact factor: 21.023

10.  Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study.

Authors:  James A Seddon; Anneke C Hesseling; Heather Finlayson; Katherine Fielding; Helen Cox; Jennifer Hughes; Peter Godfrey-Faussett; H Simon Schaaf
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

View more
  3 in total

1.  Knowledge and Attitudes of Indonesian General Practitioners Towards the Isoniazid Preventive Therapy Program in Indonesia.

Authors:  Wira Winardi; Widhy Yudistira Nalapraya; Sarifuddin Sarifuddin; Samsul Anwar; Amanda Yufika; Adityo Wibowo; Iziddin Fadhil; Hendra Wahyuni Ms; Yunita Arliny; Dewi Behtri Yanifitri; Teuku Zulfikar; Harapan Harapan
Journal:  J Prev Med Public Health       Date:  2022-08-05

2.  The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study.

Authors:  Peter J Dodd; Nyashadzaishe Mafirakureva; James A Seddon; Christopher F McQuaid
Journal:  Lancet Glob Health       Date:  2022-05-18       Impact factor: 38.927

3.  Prevention of Multidrug-Resistant Tuberculosis in Close Contacts. Back to the Future?

Authors:  Neil W Schluger
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.